Novo Nordisk enters collaboration and licensing agreement with US-based Neomorph
Under the agreement, Neomorph will receive an upfront payment from Novo Nordisk, milestone payments and funding for research and development.
by MARKETWIRE
On Monday, Novo Nordisk signed a collaboration agreement with US biotech company Neomorph to ”discover, develop and commercialize molecular glue degraders,” a press release from Neomorph in San Diego, California, reads.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
